Mindray(SZ:300760) Cai Fu Zai Xian·2025-06-30 02:01Core Insights - Mindray Medical successfully held its 2025 Investor Open Day, attracting significant attention from investors and industry professionals [1] - The company aims to continuously transform its traditional business through digitalization while expanding high-potential recurring revenue streams, focusing on an integrated solution of "equipment + IT + AI + consumables" [1] - The average growth rate of recurring revenue business over the past decade is approximately 2.5 times that of equipment business, with recurring revenue business showing significantly higher operating net profit margins [1] Group 1: Strategic Focus - The company is expanding its existing product market share in high-end markets while aggressively developing in vitro diagnostics, minimally invasive surgery, and cardiovascular recurring revenue businesses [1] - Mindray's R&D head emphasized the integration of IT and AI functionalities into medical devices to enhance customer appeal [1] Group 2: Digital Transformation - The company is leveraging AI to create a new medical ecosystem that integrates "people, machines, and objects," aiming for a comprehensive digital patient profile and tailored treatment suggestions [2] - Future plans include the release of specialized large models for anesthesia, emergency, and cardiovascular care to establish a complete clinical decision support system [2] Group 3: Business Development - The ultrasound and laboratory business leaders highlighted that AI capabilities can significantly reduce examination time and improve diagnostic accuracy [3] - Mindray is accelerating the development of more reagents to enrich its testing project portfolio, which is a key task for surpassing leading multinational companies in the next one to two years [3] - The chairman expressed a positive outlook on the long-term development prospects of Mindray and the medical device industry, citing a strong R&D team of approximately 5,000 personnel [3]